Key result
Prasugrel resolves recurrent left main stent thrombosis after poor clopidogrel response in a case report.
Why the study?
Does prasugrel prevent recurrent stent thrombosis in a clopidogrel hyporesponder?
Case Report (n=1)
Does prasugrel prevent recurrent stent thrombosis in a clopidogrel hyporesponder?
Prasugrel may be an effective alternative antiplatelet therapy for patients experiencing recurrent stent thrombosis due to clopidogrel hyporesponsiveness.
Answers are grounded in this paper and cite their sources.
May warrant prasugrel in select recurrent stent thrombosis; leaves open confirmation in prospective trials.
Stent thrombosis is a life-threatening sequela of drug-eluting stent implantation. Dual antiplatelet therapy with aspirin and thienopyridine is typically used to prevent this catastrophic event. In terms of stent thrombosis, the major concern is the variable response of patients to clopidogrel, and this has raised interest in new antiplatelet agents. We present the case of a 64-year-old woman whom we successfully treated with prasugrel after she had repeated episodes of stent thrombosis caused by a poor response to clopidogrel. This case highlights the potential role of new antiplatelet agents for patients who are undergoing drug-eluting stent implantation.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2015) conducted a case report in Recurrent left main stent thrombosis (n=1). Prasugrel vs. Clopidogrel was evaluated on Treatment of recurrent stent thrombosis. Prasugrel successfully treated recurrent left main stent thrombosis in a 64-year-old woman with a poor response to clopidogrel.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: